Zevra Therapeutics (NASDAQ:ZVRA) SVP Timothy Sangiovanni Sells 3,000 Shares of Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) SVP Timothy Sangiovanni sold 3,000 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $9.18, for a total transaction of $27,540.00. Following the sale, the senior vice president directly owned 29,590 shares of the company’s stock, valued at approximately $271,636.20. The trade was a 9.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Zevra Therapeutics Stock Down 2.4%

NASDAQ ZVRA traded down $0.22 during trading hours on Wednesday, hitting $8.94. The company’s stock had a trading volume of 882,575 shares, compared to its average volume of 1,029,253. Zevra Therapeutics, Inc. has a 52 week low of $6.19 and a 52 week high of $13.16. The company has a market capitalization of $503.32 million, a PE ratio of 19.02 and a beta of 0.99. The company has a current ratio of 8.62, a quick ratio of 8.57 and a debt-to-equity ratio of 0.46. The company’s 50-day simple moving average is $8.67 and its two-hundred day simple moving average is $9.41.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%.The firm had revenue of $26.06 million during the quarter, compared to analyst estimates of $26.64 million. Research analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Institutional Trading of Zevra Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. CWM LLC boosted its stake in Zevra Therapeutics by 399.5% in the third quarter. CWM LLC now owns 2,872 shares of the company’s stock valued at $27,000 after acquiring an additional 2,297 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in shares of Zevra Therapeutics by 30.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after purchasing an additional 1,280 shares during the period. Russell Investments Group Ltd. lifted its stake in Zevra Therapeutics by 235.7% in the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after purchasing an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares during the period. Finally, Creative Planning purchased a new stake in Zevra Therapeutics in the second quarter worth $92,000. Institutional investors own 35.03% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ZVRA shares. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Friday, January 9th. Canaccord Genuity Group reduced their price objective on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. HC Wainwright set a $26.00 target price on shares of Zevra Therapeutics in a research report on Tuesday, December 30th. Finally, Cantor Fitzgerald reduced their target price on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Zevra Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $22.80.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.